Literature DB >> 22699846

Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S.

Vincent Deramecourt1, Florence Lebert, Claude-Alain Maurage, Francisco-Jose Fernandez-Gomez, Simon Dujardin, Morvane Colin, Nicolas Sergeant, Valérie Buée-Scherrer, Fabienne Clot, Isabelle Le Ber, Alexis Brice, Florence Pasquier, Luc Buée.   

Abstract

MAPT mutations cause autosomal dominant frontotemporal lobar degeneration. These diseases are characterized by considerable heterogeneity in their clinical, neuropathological, and biochemical presentations. We describe the full characterization of a family with autosomal dominant frontotemporal lobar degeneration caused by a novel MAPT mutation. Clinical, imaging, neuropathological, and biochemical data are presented. The proband was a woman who died at 85 years old, 25 years after the onset of a slowly progressive and isolated anarthria and opercular syndrome. The pathological examination of her brain showed marked atrophy of primary motor and premotor cortices, associated with predominant neuronal tau-positive lesions mimicking Pick bodies. At the biochemical level, the six tau isoforms aggregate to display a pathological triplet at 60, 64, and 69 kDa. Two of her sons presented at 48 and 50 years old with a right temporal variant of frontotemporal degeneration characterized by severe prosopagnosia, semantic impairment, and behavioral modifications. In these three patients, the molecular analysis of MAPT showed the c.1945C>T mutation on exon 11 resulting in the P332S substitution in tau sequence. This mutation changes the PGGG motif of the third repeat domain of the protein and therefore reduces the ability of tau to bind microtubule. From a clinical point of view, this mutation is associated with considerable intrafamilial phenotypic variation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699846     DOI: 10.3233/JAD-2012-120160

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

1.  A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease.

Authors:  Pawel Tacik; Michael DeTure; Kelly M Hinkle; Wen-Lang Lin; Monica Sanchez-Contreras; Yari Carlomagno; Otto Pedraza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

2.  Tau mutants bind tubulin heterodimers with enhanced affinity.

Authors:  Shana Elbaum-Garfinkle; Garrett Cobb; Jocelyn T Compton; Xiao-Han Li; Elizabeth Rhoades
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

3.  Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Authors:  Kevin H Strang; Cara L Croft; Zachary A Sorrentino; Paramita Chakrabarty; Todd E Golde; Benoit I Giasson
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

4.  In vitro Tau Aggregation Inducer Molecules Influence the Effects of MAPT Mutations on Aggregation Dynamics.

Authors:  David J Ingham; Kelsey M Hillyer; Madison J McGuire; Truman C Gamblin
Journal:  Biochemistry       Date:  2022-06-22       Impact factor: 3.321

Review 5.  Tau and MAPT genetics in tauopathies and synucleinopathies.

Authors:  Etienne Leveille; Owen A Ross; Ziv Gan-Or
Journal:  Parkinsonism Relat Disord       Date:  2021-09-14       Impact factor: 4.402

6.  Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia.

Authors:  Eoin P Flanagan; Matthew C Baker; Ralph B Perkerson; Joseph R Duffy; Edythe A Strand; Jennifer L Whitwell; Mary M Machulda; Rosa Rademakers; Keith A Josephs
Journal:  Dement Geriatr Cogn Disord       Date:  2015-02-28       Impact factor: 2.959

7.  Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting.

Authors:  Francisco-Jose Fernandez-Gomez; Fanny Jumeau; Maxime Derisbourg; Sylvie Burnouf; Hélène Tran; Sabiha Eddarkaoui; Hélène Obriot; Virginie Dutoit-Lefevre; Vincent Deramecourt; Valérie Mitchell; Didier Lefranc; Malika Hamdane; David Blum; Luc Buée; Valérie Buée-Scherrer; Nicolas Sergeant
Journal:  J Vis Exp       Date:  2014-04-10       Impact factor: 1.355

Review 8.  The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy.

Authors:  Cheng-Cheng Zhang; Ang Xing; Meng-Shan Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-09-12       Impact factor: 5.590

9.  Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies.

Authors:  Elodie Leroux; Romain Perbet; Raphaëlle Caillierez; Kevin Richetin; Sarah Lieger; Jeanne Espourteille; Thomas Bouillet; Séverine Bégard; Clément Danis; Anne Loyens; Nicolas Toni; Nicole Déglon; Vincent Deramecourt; Susanna Schraen-Maschke; Luc Buée; Morvane Colin
Journal:  Mol Ther       Date:  2021-09-24       Impact factor: 11.454

10.  Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.

Authors:  Suzanne Lesage; Valérie Drouet; Elisa Majounie; Vincent Deramecourt; Maxime Jacoupy; Aude Nicolas; Florence Cormier-Dequaire; Sidi Mohamed Hassoun; Claire Pujol; Sorana Ciura; Zoi Erpapazoglou; Tatiana Usenko; Claude-Alain Maurage; Mourad Sahbatou; Stefan Liebau; Jinhui Ding; Basar Bilgic; Murat Emre; Nihan Erginel-Unaltuna; Gamze Guven; François Tison; Christine Tranchant; Marie Vidailhet; Jean-Christophe Corvol; Paul Krack; Anne-Louise Leutenegger; Michael A Nalls; Dena G Hernandez; Peter Heutink; J Raphael Gibbs; John Hardy; Nicholas W Wood; Thomas Gasser; Alexandra Durr; Jean-François Deleuze; Meriem Tazir; Alain Destée; Ebba Lohmann; Edor Kabashi; Andrew Singleton; Olga Corti; Alexis Brice
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.